--monoclonal gammopathy is certainly something that bears watching, but in about 65% or so of cases there is no other associated systemic disorder. In that case it is labeled "monoclonal gammopathy of undetermined signifigance" of MGUS for short.

Unfortunately, even in such cases, the rogue antibodies can interact with nerve and produce neuropathy symptoms.

This is not an easy situation to fix--either from the neuropathic standpoint or from any others. The treatments tend to be immunosuppresant, along the same lines as are used for many blood cancers, and tend to have their own significant side effects . . .unless there is evidence of a systemic disorder, treatment for any neuropathy linked to it tends to focus on symptom reduction, with a policy of "watchful waiting".